Crossref
Sickle cell drug is withdrawn over safety concerns just months after rollout
BMJ · 01.10.2024 · q2147
DOI: 10.1136/bmj.q2147 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, online erschienen am 01.10.2024. Verfasst von Elisabeth Mahase. Beteiligte Einrichtung: The BMJ. Hauptthemen laut MEDLINE: Antisickling Agents, Safety-Based Drug Withdrawals. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antisickling AgentsSafety-Based Drug WithdrawalsHumansAnemia, Sickle CellPyrazinesBenzaldehydesPyrazoles
Substanzen
Antisickling AgentsPyrazinesvoxelotorBenzaldehydesPyrazoles
Autor:innen und Institutionen
- The BMJ.
Zitieren
APA
Mahase, E. (2024). Sickle cell drug is withdrawn over safety concerns just months after rollout. BMJ, q2147. https://doi.org/10.1136/bmj.q2147
Vancouver
Mahase E. Sickle cell drug is withdrawn over safety concerns just months after rollout. BMJ. 2024:q2147. doi:10.1136/bmj.q2147
BibTeX
@article{Mahase2024,
author = {Mahase, Elisabeth},
title = {Sickle cell drug is withdrawn over safety concerns just months after rollout},
journal = {BMJ},
year = {2024},
pages = {q2147},
doi = {10.1136/bmj.q2147}
}
EUVIMED